We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Genetic Test Enables Faster Diagnosis of Rare Diseases

By LabMedica International staff writers
Posted on 28 Nov 2025

Rare disease diagnosis often involves a long and uncertain search for the underlying genetic cause. Traditional testing requires multiple separate analyses, although many patients remain without answers. A new clinical solution now offers a faster, more complete way to uncover hereditary conditions: a single test that maps the entire genome more accurately and captures complex variants that older methods miss.

The test, developed and implemented by Radboud University Medical Center (Nijmegen, Netherlands), in collaboration with Maastricht University Medical Center+ (Maastricht, Netherlands), is based on long-read genome sequencing, which measures DNA in much larger fragments and reconstructs all six billion building blocks with significantly higher completeness than short-read approaches. Radboudumc has now begun large-scale clinical use with 5,000 tests per year, initially targeting hereditary blindness and severe intellectual disabilities.


Image: Radboudumc is the first hospital in the world to use a new genetic test on a large scale in clinical practice (Photo courtesy of Radboudumc)
Image: Radboudumc is the first hospital in the world to use a new genetic test on a large scale in clinical practice (Photo courtesy of Radboudumc)

Study findings show that long-read sequencing increases diagnostic yield by more than ten percent for some rare diseases and can detect structural variations that are difficult to identify with conventional methods. The technique also captures DNA modifications that influence gene activity, offering deeper insight into disease mechanisms. Research suggests that ongoing analysis of these full-length genomes could raise the diagnostic uplift to as high as fifteen percent. Published evidence from genomic technology studies supports its suitability and reliability for routine clinical practice.

The introduction of this test is expected to replace around fifteen separate diagnostics, reduce time to diagnosis, and help uncover new hereditary causes of disease. For families, a definitive diagnosis brings clarity, emotional relief, and improved ability to connect with others facing similar conditions. Clinicians can also better assess future reproductive risk and provide more accurate prognostic information. As long-read sequencing becomes a new clinical standard, hospitals anticipate earlier answers and more comprehensive genetic insights for thousands of patients each year.

“Long read sequencing can replace fifteen other genetic tests in clinical practice, making diagnostics faster and more efficient,” said Professor of Genomic Technologies Alexander Hoischen. “I expect this will become the new standard for genome diagnostics and the only test we’ll perform in the future.”

Related Links:
Radboud University Medical Center
Maastricht University Medical Center+ 


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Hematology Analyzer
Medonic M32B
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88

Latest Molecular Diagnostics News

Urine Test Detects Inherited Neuropathy Missed by Genetic Screening
28 Nov 2025  |   Molecular Diagnostics

Genomic Test Predicts Risk of SCC Metastasis
28 Nov 2025  |   Molecular Diagnostics

Microfluidic Device Predicts Pancreatic Cancer Recurrence After Surgery
28 Nov 2025  |   Molecular Diagnostics



GLOBE SCIENTIFIC, LLC